Background: There is an increasing evidence to suggest that inflammation plays a pivotal role linking early vascular injury to the eventual consequence of neointimal growth and lumen compromise. The widespread use of drug-eluting stents has fundamentally altered the vascular response to injury by causing a more intense and prolonged inflammatory state. We examined the anti-inflammatory effects of abciximab-coated in a porcine coronary overstretch restenosis model. Methods: Six abciximab-coated stents, six sirolimus-eluting stents (SES), and six paclitaxel-eluting stents (PES) were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries, and histopathologic analysis was assessed and correlated with neointimal formation at 28 days after stenting. Results: At 28 days, the lumen area was 17.7짹4.3, 17.4짹5.1, and 18.6짹7.8 mm2, and neointima area was 1.9짹0.9, 2.4짹1.2, and 2.7짹1.5 mm2, and percent area stenosis was 10.2짹5.4, 12.1짹6.1, and 13.9짹8.8% in abciximab-coated stent, SES, and PES group, respectively (p=NS). In neointima, most inflammatory cells were lymphohistiocytes. A significant positive correlations were found between the extent of inflammatory reaction and the neointimal thickness (r=0.65, p<0.001), neointimal area (r=0.55, p=0.001) and percent area stenosis (r=0.62, p<0.001). The number of inflammatory cells in neointima was 92.7짹33.1, 104.0짹43.2, and 193.3짹56.9 in abciximab-coated stent, SES, and PES group, respectively (p=0.485 in abciximab vs. SES, 0.050 in abciximab vs. PES, 0.096 in SES vs. PES, respectively). Conclusion: The inflammatory reaction plays an important role in neointima formation, and abciximab-coated stents inhibit inflammatory reaction effectively after coronary stenting.